The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2020 financial results and provide an operational update
VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39% , respectivel y, and k ey secondary composite first hard MACE , comprised of
Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of new data at European Atherosclerosis
DUBLIN, Ireland and BRIDGEWATER, N.J. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero , Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday,
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation.
VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients VASCEPA in REDUCE-IT® cardiovascular outcomes study achieved statistical significance for primary and secondary endpoints at predefined blinded first
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides further insight to potential mechanisms of action VASCEPA is the first and only agent studied on top of
Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on laboratory-confirmed viral upper respiratory infection (URI) rates,
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead Focused Launch DUBLIN, Ireland and BRIDGEWATER, N.J., Aug.